Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

BACKGROUND: Although pemetrexed, a potent thymidylate synthase (TS) inhibitor, enhances the cytoytoxic effect of platinum compounds against malignant pleural mesothelioma (MPM), novel combinations with effective targeted therapies are warranted. To this end, the current study evaluates new targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannetti, E, Zucali, P A, Assaraf, Y G, Leon, L G, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A, Peters, G J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242521/
https://www.ncbi.nlm.nih.gov/pubmed/21970874
http://dx.doi.org/10.1038/bjc.2011.400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242521/
https://www.ncbi.nlm.nih.gov/pubmed/21970874
http://dx.doi.org/10.1038/bjc.2011.400

Ejemplares similares